Quest Diagnostics®



Advancing multi-cancer risk assessment through clinical and diagnostic collaboration

Using biomarkers identified by MD Anderson, Quest Diagnostics has developed a multi-cancer stratification test to improve earlier cancer risk identification

Quest and The University of Texas MD Anderson Cancer Center have formed a strategic alliance that combines complementary capabilities in research, assay development, and national laboratory scale to advance the Multi-Cancer Risk Test.

MD Anderson contributes pre-test development, clinical research, and longitudinal patient data, while Quest applies expertise in the clinical test development, validation, and broad clinical deployment of the assay. The work aims to address persistent gaps in preventive oncology by enabling accessible risk assessment across diverse care settings.

THE CHALLENGE

Early cancer detection faces 2 major barriers:

- Adherence to recommended screening remains low, often because procedures can be invasive, inconvenient, or costly[1]
- Several high-mortality cancers—including pancreatic cancer—lack established routine screening approaches[2]

As a result, many malignancies are identified at advanced stages, limiting treatment options and survival.

THE SOLUTION

Multi-Cancer Risk Test is a laboratory-developed blood test designed to stratify risk for multiple cancers from a single sample. By measuring circulating protein biomarkers, the assay identifies individuals at elevated risk for 9 cancers, including several without standard screening pathways.

The test is intended to complement existing screening modalities by helping clinicians identify patients who may benefit from further diagnostic evaluation or closer surveillance.

MD Anderson: Clinical discovery and validation

- Clinically validated biomarkers and outcome-linked patient cohorts
- Data supporting algorithm development and risk stratification

Quest: Assay development, scale, and clinical implementation

- Assay development, analytical validation, test optimization, and national-scale lab operations
- Consistent clinical performance and longitudinal risk assessment through repeat testing

Outcomes and impact: Building the pathway to real-world multi-cancer risk assessment

Multi-Cancer Risk Test is designed to provide a practical way to identify individuals who may be at elevated risk for cancer using a single blood draw. By helping clinicians determine who may benefit from further evaluation, the approach has the potential to support earlier investigation and more focused use of diagnostic resources.

Repeat testing over time may also enable longitudinal insight, giving care teams a structured way to monitor how risk evolves. As with any emerging approach, continued evidence development will be essential to support informed integration into practice.

BY THE NUMBERS

The work between Quest and MD Anderson Cancer Center reflects translational medicine in practice, connecting academic investigation with the CLIA requirements of clinical test development and validation to enable large-scale clinical application. MD Anderson contributes clinically validated biomarkers and deeply characterized patient cohorts, while Quest provides the capabilities needed to develop, operationalize, and evaluate the test in broader care environments.

Beyond advancing a single assay, the collaboration helps define a sustainable and scalable approach for how innovations in preventive oncology can move from discovery toward real-world use.



Only 51%
of US adults report having a routine cancer screening in 2025[3]

9 types of cancer assessed by the Multi-Cancer Risk Test

1 in 3
adult Americans served annually by Quest[4]

Learn more at **QuestDiagnostics.com/Business-Solutions/Hospitals-Health-Systems/Academic-Collaboration**

References

1. Modi S, Bhimineni C, Choradia N, et al. Adherence to cancer screening programs across the US. *JCO Oncology Practice*. 2025;21(10_suppl):163-163. doi:10.1200/op.2025.21.10_suppl.163
2. Pancreatic Cancer Action Network. Pancreatic cancer early detection. Accessed February 10, 2026. https://pancan.org/facing-pancreatic-cancer/diagnosis/early-detection
3. Routine medical appointments and cancer screenings head in the wrong direction. *Prevent Cancer Foundation*. April 8, 2025. Accessed February 10, 2026. https://preventcancer.org/news/routine-screenings-wrong-direction/
4. Quest Diagnostics. 2022. Accessed February 10, 2026. https://www.QuestDiagnostics.com/our-company/about-us

Image content features a model and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest Diagnostics®